

# Amylase (Liquid)

## 1.0 INTENDED USE

This reagent is intended for the quantitative determination of a-Amylase activity in serum.

## 2.0 BACKGROUND

### 2.1 METHOD AND HISTORY


The classic method of determining a-Amylase activity is enzymatic hydrolysis of a starch substrate followed by product analysis. The saccharogenic analysis method (10.2,10.3) measures the quantity of reducing sugars formed. There are difficulties associated with this method such as inconsistent results due to variations in substrate preparation and treatment.

Other methods of analysis include the dye-starch substrate methods(10.4) and the amyloclastics methods (10.5). Each has drawbacks (10.6,10.7). Modified saccharogenic methods have been introduced recently which utilize a defined oligosaccharide substrate. These substrates produce colorimetric products when coupled with p-nitrophenyl. Wallenfels et al(10.11) introduced p-nitrophenylglycosides as defined substrates for a-amylase determination in a procedure that eliminates interference from endogenous glucose and pyruvate.

### 2.2 TEST PRINCIPLE

The present method is based on the use of a chromogenic substrate, 2-chloro-p-nitrophenol linked with maltotriose. The reaction of amylase with this substrate results in the formation of 2-chloro-p-nitrophenol, which can be measured spectrophotometrically at 405nm. This reaction proceeds very rapidly, no coupling enzymes are required, and the reaction is not readily inhibited by endogenous factors.

a-amylase



a-Amylase hydrolyzes the 2-chloro-p-nitrophenyl-a-D-maltoheptaoside (CNPG3) to release 2-chloro-nitrophenol and form 2-chloro-p-nitrophenyl-a-D-maltoside (CNPG2), maltotriose (G3) and glucose (G). The rate of increase in absorbance is measured at 405nm and is proportional to the a-amylase activity in the sample.

### 2.3 CLINICAL SIGNIFICANCE

Assay for the a-Amylase activity are of interest for the evaluation of pancreatic function of the diagnosis of pancreatic disease. The greatest elevation in serum a-Amylase activity is seen in acute pancreatitis and obstruction of pancreatic duct (10.1).

## 3.0 SPECIMEN COLLECTION AND HANDLING

### 3.1 PATIENT PREPARATION

No special patient preparation is required.

### 3.2 SPECIMEN COLLECTION.

3.2.1 Unhemolyzed serum is the specimen of choice. Specimens should be collected as per NCCLS document H4-A3(10.12).

3.2.2 Anticoagulants, such as Citrate and EDTA, bind calcium which is needed for amylase activity. Therefore, plasma with these anticoagulants should not be used.

### 3.3 SPECIMEN STORAGE

Amylase in serum is reported stable for one week at room temperature (18-26°C) and for two months when stored refrigerated at 2-8°C.(10.1)

It is recommended that testing be done as soon as possible after sample collection and preparation. If testing cannot occur immediately, store the sample properly using the guidelines above.

## 4.0 MATERIALS

(1 X 60 ml)

(2 X 125 ml)

Reagents necessary for the determination of a-Amylase are included in the kit.

### 4.1 REAGENT

a-Amylase reagent contains:

MES Buffer	ph 6.0 ± 0.1
2-Chloro-p-nitrophenyl-a-D-maltotrioside	1.8 mM
sodium chloride	350 mM
calcium acetate	6 mM
Potassium thiocyanate	900 mM
sodium azide as preservative	0.01%

### 4.2 WARNINGS AND PRECAUTIONS

4.2.1 This reagent kit is intended for in vitro diagnostic use only.

4.2.2 This reagent contains potassium thiocyanate. POISON. Do not ingest.

4.2.3 This reagent contains sodium azide (0.01%) as a preservative. Do not ingest. May react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with a large volume of water to prevent azide build up.

4.2.4 All specimens and controls should be handled as potentially infectious, using safe laboratory procedures. (NCCLS M29-T2)(10.13).

### 4.3 REAGENT PREPARATION

The reagent is provided as a ready-to-use liquid. No preparation is required.

### 4.4 REAGENT STORAGE AND STABILITY

4.4.1 Store reagent at 2°-8°C.

4.4.2 The reagent is stable until the expiration date if stored as directed. When stored at 2°-8°C unopened reagents are stable until the expiration date printed on the label.

4.4.3 Do not use if the absorbance of the reagent is greater than 0.600 when measured at 405nm against water in a cuvette with a 1cm path length or if the reagent fails to meet stated parameters of performance.

4.4.4 Do not use if the reagent is turbid or displays other evidence of bacterial contamination.

**4.5 ADDITIONAL MATERIALS REQUIRED**

4.5.1 A spectrophotometer or colorimeter capable of reading absorbance accurately at 405 nm.

4.5.2 1 cm cuvettes or a flow cell capable of transmitting light at 405 nm.

4.5.3 Test tubes capable of holding 2 ml.

4.5.4 Pipettes capable of delivering 1 ml and 25 µl.

4.5.5 Timer with 30 second increments.

4.5.6 Constant temperature heat source which can be adjusted to 37° C.

4.5.7 King normal and abnormal controls for quality control.

**5.0 TEST PROCEDURE**

The following is a general procedure for use on a manual instrument.

**5.1 PROCEDURE CONDITIONS**

Wavelength	405 nm
Temperature	37° C
Pathlength	1 cm
Mode	Kinetic
Reaction Time	2 min.
Sample Volume	25 µl
Reagent volume	1.0 ml
Total Volume	1.025 ml
Sample to reagent ratio	1/40

**5.2 INSTRUMENT**

Any instrument capable of reading absorbance accurately with a sensitivity of 0.001 absorbance at 405 nm may be used. The band width should be 10 nm or less, stray light 0.5% or less, and the wavelength accuracy within 2 nm.

**5.3 CALIBRATION**

No reagent calibration is necessary as this method is standardized by means of the molar absorptivity of 2-chloro-p-nitrophenyl taken as 12.9 at 405nm under the test conditions described.

**5.4 PROCEDURE**

5.4.1 Pipette 1.0ml of reagent into tubes labelled "control", "patient", etc. DO NOT PIPETTE BY MOUTH.

5.4.2 Pre-incubate all tubes at 37°C for at least five minutes.

5.4.3 Zero spectrophotometer with water at 405nm.

5.4.4 Add 0.025ml (25µl) of sample and read after 30 seconds.

5.4.5 Record the absorbance at 30 second intervals for 2 minutes.

**5.5 CALCULATION AND RESULTS**

Amylase U/L =

$$\frac{\Delta A/\text{min} \times \text{assay volume (ml)} \times 1000}{12.9 \times \text{light path (cm)} \times \text{sample volume (ml)}} = \Delta A/\text{min} \times 3178$$

12.9 X light path (cm) X sample volume (ml)

ΔA/min = change in absorbance per minute

assay volume = 1.25 (ml)

1000 = converts U/ml to U/L

12.9 = absorbance coefficient of 2-chloro-p-nitrophenyl at 405 nm

lightpath = 1 (cm)

sample volume = 0.025 (ml)

3178 = factor derived from constants in the equation

Example:

$$\text{Amylase U/L} = \frac{0.019 \times 1.02 \times 1000}{12.9 \times 1 \times 0.025} = 0.019 \times 3178 = 60 \text{ U/L}$$

**6.0 INTERPRETATION OF RESULTS**

**6.1 EXPECTED VALUES (10.9)**

The range of expected values is:

$$25 - 125 \text{ U/L (37 degrees C)}$$

These values are suggested guidelines. It is recommended that each laboratory establish the normal range for the area in which it is located.

**6.2 MEDICAL ALERT VALUES (10.10)**

Each laboratory should establish low and high values beyond which the patient would require immediate attention by a physician. If a "medical alert value" is reached, always repeat the test to confirm the result and notify a physician if the result is confirmed.

**6.3 LIMITATIONS OF PROCEDURE**

Young (10.8) gives a list of drugs and other substances that interfere with the determination of amylase activity.

**7.0 QUALITY CONTROL**

Standard practice for quality control should be applied to this system. Commercially available lyophilized controls can be used to monitor the daily acceptable variations. Biotron normal and abnormal controls should be assayed at the beginning of each run of patient samples, whenever a new reagent or a different lot number is being used, and following any system maintenance.

A satisfactory level of performance is achieved when the analyte values obtained are within the "acceptable range" established by the laboratory.

#### 8.0 CALIBRATION PROCEDURES

No routine reagent calibration is necessary as this method is standardized by means of the molar absorptivity of 2-chloro-p-nitrophenyl taken as 12.9 at 405nm under the test conditions described.

The results obtained when measuring the activity of a kinetic reaction are based on the change in absorbance per minute. In order to accurately monitor and report this reaction rate, the operating parameters of the spectrophotometer (wavelength, temperature of the reaction and timing of the test) must be known and controlled.

#### 9.0 PERFORMANCE CHARACTERISTICS

##### 9.1 PRECISION

The estimates of precision shown below were performed following the guidelines contained in NCCLS document EP5-T2(10.14).

Within-Run		
<u>Mean (U/L)</u>	<u>SD (U/L)</u>	<u>CV (%)</u>
14	± 0.5	3.6
106	± 0.7	0.7
418	± 1.1	0.3
1392	± 7.8	0.6

Between-Run		
<u>Mean (U/L)</u>	<u>SD (U/L)</u>	<u>CV (%)</u>
15	± 0.7	4.7
109	± 2.3	2.1
421	± 5.6	1.3
1413	± 16.6	1.2

## 9.2 CORRELATION

A correlation study was done comparing this method (y) and a similar comparative method (x). The samples (n=125) ranged from 32 to 2112 U/L. The study yielded a regression curve of  $x = 0.98x + 5.4$  with a correlation of 0.999.

Note: CNPG3 values greater than 2000 U/L were run after dilution with an equal volume of saline.

## 9.3 LINEARITY

Linearity: This procedure is linear through 2000 U/L beyond which the specimen should be diluted with an equal volume of saline. Reassay the specimen and multiply the results by 2.

## 9.4 SENSITIVITY

A change in absorbance of 0.003  $\Delta A/\text{min}$  at 405nm at 37° C corresponds to 9.53 U/L.

## 10.0 REFERENCES

- 10.1 Tietz, N.W., (Editor) Fundamentals of Clinical Chemistry, W.B. Saunders Company, Philadelphia (1982).
- 10.2 Somogyi, M., J. Biol. Chem., 125:399 (1938).
- 10.3 Henry, R.J., Chiamori, N., Clin. Chem., 6:434 (1960).
- 10.4 Klein, B., Foreman, J., Seary, R., Clin. Chem., 16:32 (1970).
- 10.5 Somogyi, M., Clin. Chem., 6:23 (1960).
- 10.6 Kaufman, R.A., Tietz, N.W., Clin. Chem., 26:846 (1980).
- 10.7 Rauscher, E., Neumann, U., Schaich, E., von Bulow, S., Wahlefeld, A.W., Clin. Chem., 31:14 (1985).
- 10.8 Young, D.S., Effects of Drugs on Clinical Laboratory Tests, 3rd ed., Washington DC, AACC Press (1990).
- 10.9 Tietz, N.E., (Editor) Clinical Guide to Laboratory Tests, W.B. Saunders Company, Philadelphia (1983) p. 54.
- 10.10 G.J. Kost, "Critical Limits for Urgent Clinician Notification at U.S. Medical Centers"; JAMA, Feb. 2, 1990; Vol 263, No.5, p.704
- 10.11 Wallenfels, K., et al, Carbohydrate Research 61:359 (1978).
- 10.12 NCCLS documents "Procedures for the Collection of Diagnostic Blood Specimens by Abin Puncture" 3rd Ed (1991).
- 10.13 NCCLS documents "Protection fo Laboratory Workers from Infectious Disease Transmitted by Blood, Body Fluids and Tissues" 2nd Ed (1991).
- 10.14 NCCLS document "Evaluation of Precision Performance of Clinical Chemistry Devices" 2nd Ed (1992).